Nufarm Limited (NUF) Earnings Call Transcript & Summary
May 27, 2026
What were the key takeaways from Nufarm Limited's May 27, 2026 earnings call?
Nufarm Limited reported strong first half results for FY '26, with an 18% increase in EBITDA to $243 million and a 35% rise in NPAT to $52 million. Despite a year-on-year revenue decline due to a strategic focus on margin over volume, gross profit increased by 7%, achieving a record gross margin of 33.1%. Management reaffirmed their full-year guidance, expecting continued EBITDA growth and targeting a net debt leverage of 2x by year-end, down from 2.7x in FY '25.
What topics did Nufarm Limited cover?
- Strong EBITDA Growth: Nufarm achieved an 18% increase in underlying EBITDA to $243 million, driven by improved earnings quality and capital discipline. CEO Rico Christensen stated, "This overall performance gives us the confidence to reaffirm our outlook for the full year in regards to strong growth in underlying EBITDA."
- Margin Improvement: The gross profit margin expanded to 33.1%, the highest in 20 years, reflecting a strategic shift towards higher-margin products. CFO Brendan Ryan noted, "This margin expansion, combined with disciplined cost management, is now translating into strong operating leverage across the P&L."
- Revenue Decline: Revenue decreased year-on-year as management prioritized margin over volume, indicating a deliberate strategic choice. Ryan mentioned, "While revenue was lower year-on-year, reflecting our deliberate focus on improving mix and prioritizing margin over volume."
- Free Cash Flow Improvement: Free cash flow improved significantly by $193 million year-on-year, attributed to stronger profitability and better working capital management. Ryan stated, "This improvement has been driven by stronger profitability, improved working capital outcomes contributing to $103 million and lower capital expenditure."
- Cost Savings Program: Nufarm is on track to deliver a $50 million cost savings program, with $32 million already achieved in the first half. Management emphasized ongoing cost discipline as a key part of their strategy refresh, with Ryan stating, "We are on track to deliver 2025 cost savings program, with the full period benefit of $50 million captured by this financial year-end."
What were Nufarm Limited's May 27, 2026 results?
- Revenue: null (lower year-on-year due to strategic focus)
- EBITDA: $243 million (up 18% YoY)
- NPAT: $52 million (up 35% YoY)
- Gross Margin: 33.1% (highest in 20 years, up 3.7 percentage points)
- Free Cash Flow: $193 million (improvement year-on-year)
- Net Debt: null (reduced 10% YoY)
Nufarm's strong first half performance and strategic focus on margin improvement position the company well for continued growth. The reaffirmed guidance and ongoing cost discipline are positive signals for investors. However, the reliance on higher-margin products and potential external cost pressures present risks to watch in the upcoming quarters.
Earnings Call Speaker Segments
Thank you, Ashley. Good morning, and thanks for being with us today as we cover Nufarm's first half FY '26 results. Joining me are Brendan Ryan, our CFO; Beth Lorsbach, Group Executive for Portfolio Solutions; and Rachel Palumbo, General Manager of our Hybrid Seeds business. Over this past year, we've been quite deliberate about sharpening where we focus so that earnings quality improves, the balance sheet gets stronger, and capital discipline increases. What we're presenting today shows solid progress along that path. I'll take you through how the first half went. Brendan will follow with a closer look at the financials. And finally, I'll cover our strategy refresh and wrap up with comments on the outlook. Before we start, I'd encourage everyone to read the important notices on the next page about forward-looking statements and non-IFRS measures. As usual, what we say today is subject to market conditions and the risks set out in this presentation. I'm happy to report a strong result: EBITDA grew 18% and NPAT grew 35% over the prior corresponding period; we also achieved a substantial free cash flow improvement of $193 million, bringing leverage down to 3.6x net debt to underlying EBITDA, which beats last year and matches the first half of FY 2024. Revenue came in lower year-on-year, which reflects a deliberate emphasis on better mix and on margin rather than volume. Gross profit rose 7% to a margin of 33.1%, the highest gross profit percentage Nufarm has reported in the last 20 years. Later on, we'll go into more detail about the strategic choices behind the change in our margin profile and where our focus goes from here. Happily, this overall performance gives us confidence to reaffirm the full-year outlook for strong growth in underlying EBITDA and 2x leverage. Last November, we set out our priorities for FY 2026: cost and capital discipline, profitable growth in Crop Protection, and delivery on our reprioritized seed strategy. We have done what we said we would. Cash flow improved and leverage came down to 3.6x, and operating expenses stayed flat. In Crop Protection, we achieved profitable growth and better margins. EBITDA there grew 6% in constant currency. Hybrid Seeds EBITDA rose 8%, and Emerging Platforms performance improved significantly. Crop Protection delivered a good result, with growth coming from underlying regional strength, partly offset by currency translation and weather impacts. Performance varied by region, but one thing has been consistent: we concentrate resources where sustainable margins and returns are achievable; that discipline shows up more and more in earnings quality and cash outcomes and produced a 6% increase in EBITDA in constant currency. Europe stood out, with EBITDA up 17% versus the prior corresponding period in local currency, reflecting a better product mix and lower operating costs after the performance improvement program was implemented. EBITDA for North America rose 11% versus the prior corresponding period in local currency. Turf & Ornamental along with Canada posted strong growth. U.S. Crop Protection volumes showed the ongoing emphasis on higher value products. New product revenue timing was affected by longer regulatory approval processes. APAC EBITDA fell 15% against the prior corresponding period, mainly due to dry weather conditions in Australia and currency headwinds. Within Asia, underlying EBITDA rose strongly in constant currency, and Indonesia was a key contributor. Seed Technologies has us very pleased. EBITDA was up 8%, lifted by Hybrid Seeds growth and a materially improved result in Emerging Platforms. Hybrid Seeds did well across all crops, with expansion and scale-up in South America, strong Australian canola growth and successful new product launches. On Emerging Platforms, we extended our offtake agreement with bp through 2050. That positions carinata to grow at scale under a disciplined capital-light investment model; in omega-3, we cut cash cost and capital; omega-3 is being repositioned toward lower cost of production in North America. Deregulation in Europe and China remains on track for 2028. Taken together, Seed Technologies is delivering higher quality earnings with improved margins and lower capital intensity. I'll now pass things to Brendan, who will take us through the financial results in detail.
Thanks, Rico. Like Rico said, we've had a strong first half—better earnings, stronger cash flow, and less leverage. What the financials I'm about to walk you through demonstrate is that those results stem from higher-quality earnings and more disciplined capital allocation—deliberate moves we've made over the last 12 months to reshape the business. Turning to the P&L: revenue declined compared with a year earlier, reflecting our intentional focus on enhancing mix and prioritizing margin over volume, yet gross profit climbed 7%, and margins expanded 3.7 percentage points, reaching 33.1%. That improvement comes from a stronger mix in Crop Protection, robust growth in Hybrid Seeds, and better results in omega-3. What matters here is that this wider margin, combined with tight cost control, is now producing significant operating leverage throughout the P&L, and those margin improvements are carrying through into earnings. Operating expenses stayed roughly level, since savings from the cost program more than made up for inflationary pressure. That gave us underlying EBITDA of $243 million, up 18%, while underlying EBIT climbed 32% to $136 million. Underlying net profit after tax also grew strongly, rising 35% to $52 million, showing the earnings leverage that is now built into the business. Taken together, this shows better quality and greater resilience in our earnings profile, and that is converting into cash more and more. Turning to the balance sheet, we're now clearly past the cyclical high in working capital that we saw in the first half of financial year '24. This better balance sheet efficiency is helping us generate stronger cash. Average net working capital declined 12%, and net working capital to sales improved by 2.1 percentage points, which reflects disciplined management of working capital. Meanwhile, capital expenditure has dropped materially as we shift from a peak investment period to a lower, more sustainable level. Together with stronger profitability, that has produced a meaningful decrease in net debt and leverage. Net debt was down 10% compared with the prior year, even with an opening net debt position for financial year '26 that was $190 million higher. Leverage went from 4.5x to 3.6x — a reduction of roughly 20%. Broadly, the balance sheet is getting stronger thanks to better working capital efficiency, and the business is set up to keep deleveraging, powered by earnings and cash generation. Turning to net operating expenses, we remain on track to deliver the 2025 cost savings program, and its full-period benefit of $50 million will be captured by this financial year-end. As the slide shows, we delivered $32 million in cumulative operating expense savings through the first half of the year, which has offset inflation. It's worth noting that a substantial share of those savings now sits within the current earnings base, feeding straight into underlying EBITDA growth. The savings came from focused moves throughout the business — performance improvement work in Europe, lower commercial and support expenditure, and a headcount that is 115 below last year. Taken together, the program is helping margins, cash flow and returns keep improving. Moving to cash flow: free cash flow for the half reflects the typical working capital build we see in the first period; we delivered 133 — sorry, $193 million of free cash flow improvement year on year, which reflects materially stronger underlying cash generation as well as disciplined capital management. Stronger profitability has driven this improvement, together with better working capital outcomes that contributed $103 million and lower capital expenditure. Importantly, this amounts to a strong lift in underlying cash generation and puts us in good shape for positive free cash flow across the full year as working capital unwinds during the second half. Turning to net working capital, we posted a further year-on-year gain as we keep delivering sustained improvement from the cyclical peak reached in the first half of financial year '24. Average net working capital came down by 7%, and the cash conversion cycle improved by 6 days, driven primarily by lower receivable days, which produced lower funding requirements and better capital efficiency. As a result, net working capital to sales declined 2.1 percentage points, and it is now well within our 35% to 40% target range. This improvement underscores the headway we are making in instilling capital discipline across the business, and working capital will stay a key lever underpinning free cash flow generation. Regarding capital expenditure, the cut we have implemented this year mirrors our shift out of a peak investment period into a lower, more sustainable level of spending; it also mirrors our more focused strategy, which requires reduced capital intensity and stronger discipline in capital allocation. That encompasses decreased spending throughout manufacturing, a more concentrated Crop Protection R&D portfolio, and less investment in the omega-3 platform. Looking at this year, our capital expenditure target is under $200 million, compared with $246 million the prior year. Because of how project delivery is timed, you'll notice the spend is weighted toward the second half. A more sustainable capital profile for the business will help us generate better free cash flow as time goes on. Turning to net debt, we achieved a $135 million decrease versus a year ago, even with a higher opening debt position and some currency translation benefit, and leverage came down roughly 20%, moving from 4.5x to 3.6x. That comes from a combination of stronger earnings, disciplined working capital management and reduced capital expenditure. What matters here is that the reduction in leverage is coming from better earnings and stronger cash generation, not just from actions on the balance sheet—and that represents a real change in the company's financial profile. On the funding side, we're in a strong position, with a diversified capital structure that is covenant-light. Liquidity is still solid even after we carried the seasonal working capital build. Next, some details to assist with your models—guidance on a few key line items for the full year of financial year '26. Depreciation and amortization: roughly $218 million. Net interest expense: about $100 million. Foreign exchange hedge expense: the second half is expected to come in lower than the first half. Underlying income tax expense: we expect a range of $20 million to $30 million, reflecting country mix. All in all, this outcome shows better earnings quality, substantially stronger cash generation, and a sturdier balance sheet; that backs our confidence in meeting the full year outlook. We're now constructing a more resilient financial profile, with operating leverage and cash conversion both improving. That gives us a solid base for continued deleveraging, sustained free cash flow, and better returns over time, and it shows the strategy is already turning into financial results. I'll now pass you back to Rico, who will cover the strategy refresh and the outlook.
Thanks, Brendan. I'll talk through the strategy refresh now, then move on to outlook. Whenever I consider Nufarm and speak with growers and channel partners around the globe, the thing that really stands out is how instantly people recognize and respect our brand, plus how deep the relationships are that we've built through over 100 years in business. Our solutions are well known, as is our dedication to being simple to work with; we lead in important geographies across core crops and key product segments. People know and respect us for innovation in crop protection and seeds, and for backing customers with solutions as agriculture keeps changing. With this strategy refresh, we're going to take the strongest parts of what we already have and what we already do, and place greater emphasis there so we can deliver improved returns for shareholders. Over the years, our industry has slid toward an everything for everybody model. We're taking a different route. What we're laying out involves not only deciding what we will do but also deciding what we won't do — honing in on the areas where we can win and instilling greater discipline in how capital and resources are allocated as a result. First, we're putting capital to work more effectively, moving it toward markets where we've demonstrated a track record of strong returns and where we hold a competitive advantage. This also involves divesting assets and portfolios whenever they fail to align with our strategy and our approach to returns discipline. Second, we are raising the caliber of earnings and returns within Crop Protection. That requires sharpening our focus on crops and markets; and as these results demonstrate, we are prioritizing margin over volume. We will continue renewing the portfolio through partnerships that deliver innovation via a capital-light model. Third, in Hybrid Seeds we have a strong-quality business with a well-defined path to growth. Within Emerging Platforms, we occupy a distinctive position, with technologies that are in demand and supported by strategic partners such as bp. In that area, we have adopted a more disciplined stance on investments that underpin growth and group returns. Broadly speaking, this refresh is designed to underpin stronger cash generation, improved margins and better ROFE as time goes on; in FY '26 we remain focused on disciplined delivery, completing the earlier $50 million cost savings program announced in FY '25, resetting our CapEx target to below $200 million and continuing toward lower leverage. The strategy refresh sets the stage for additional efficiencies. In April we announced a further $50 million of cost savings and expect to hit that run rate by the end of FY '27, with the full benefit in FY '28; in FY '27 we expect CapEx to remain at a level similar to FY '26. Beyond that, we want to stay free-cash-flow positive, keep enhancing ROFE, and operate with leverage in the neighborhood of about 1.5 to 2x. Those objectives, taken together, reflect the financial discipline embedded in the refreshed strategy and our resolve to improve returns and cash generation across the cycle. I'll share a bit more detail about the new cost savings program. The FY '26 program focuses on 2 areas. One is rationalizing assets and the portfolio; the other involves operational efficiency and modifications to our operating model. The savings we expect are divided between a lower internal cost of goods and reduced SG&A. I'd like to emphasize that hitting our savings goal isn't reliant on outside decreases in the cost of goods. For the FY '26 program, we anticipate cash implementation costs of $15 million, with the majority falling in FY '27. By the conclusion of FY '27, we expect to achieve the run rate savings, and the complete benefit should come through in FY '28. Within our Crop Protection business, a number of steps have been implemented after the strategy refresh. First, we're concentrating the portfolio on a smaller set of crops and shifting capital priorities toward markets where we can reliably generate returns exceeding our cost of capital. Second, we're actively streamlining assets so that our footprint lines up better with that portfolio. That covers shutting down the Wyke Butyrics operation as well as closing the Kwinana site and putting it up for sale. We're still evaluating other footprint possibilities. Alongside that, we're streamlining our North American portfolio so that higher-margin products get priority. As part of this, we're intentionally forgoing a portion of short-term revenue and focusing instead on expanding those higher-margin products, which our first half results demonstrate. Third, we're pursuing ongoing operational efficiency — reducing fixed cost, capital intensity and complexity. All together, these steps are meant to move capital into activities with better returns and to produce margins and returns that are more resilient over time. At Seed Technologies, we're also taking steps to strengthen capital discipline and returns while keeping the long-term upside intact; we reorganized the portfolio into two separate operating models, since the routes to market, customer archetypes and capital profiles differ considerably. Hybrid Seeds centers on scaling our platform with the strongest returns, with a pronounced Southern Hemisphere tilt; this is a traditional business-to-retail setup in which we shape grower choices at the farm gate. Steps already in motion include simplifying the European sunflower operation via a licensing approach and growing in South America, both meant to lift margins and returns while seizing on mounting worldwide demand for plant-based oils. Emerging Platforms follows a business-to-business approach built on a chosen set of distinctive strategic partners. We're intentionally taking a more disciplined path here. When it comes to carinata, we're supporting growth through a broader partnership with bp, using a capital-light model. For omega-3, we've reduced cash spend and moved to a staged approach, with production and deregulation advancing in a measured way, while the long-term growth prospects stay intact. Together, these steps are designed to boost returns while preserving strategic flexibility. That brings us to our strategic priorities, which are still cost and capital discipline, profitable growth in Crop Protection, and delivering on the reprioritized seeds strategy. To back that up, we've outlined a number of specific actions that are already underway. First is an added cost savings program totaling $50 million, and we have shared the details on that. We have also made quite solid progress in resetting CapEx to a healthier level and steering it toward our chosen markets. Improving earnings quality and raising free cash flow also stay a continuing focus. Within Crop Protection specifically, we are moving the portfolio mix toward higher-margin products. In the U.S., we constructed a solid plan for better returns and are now in the early stages of carrying it out. In Europe, we achieved quite good progress on margins and returns during this first half, and at this point we are focused on keeping that momentum going. Within Seeds, we're building a fresh operating structure centered on those two separate businesses, and at the same time we're growing our Hybrid Seeds operation across the Southern Hemisphere. Our investments are guided by a returns-driven approach, yet we're keeping long-term growth opportunities in Emerging Platforms firmly in view. That leads into our FY '26 outlook. For this year we're reaffirming the guidance, expecting robust EBITDA growth. By the end of FY '26 our goal is net debt leverage of 2x, compared with 2.7x at the close of FY '25. We also expect free cash flow to be positive, helped by the usual seasonal release of working capital, and capital expenditure is targeted at under $200 million. For Crop Protection, we expect EBITDA to keep rising, with the second-half growth rate exceeding what we saw in the first half, supported by ongoing margin gains and cost reductions. For Seed Technologies, we look for robust EBITDA growth from Hybrid Seeds, along with a $40 million EBITDA boost from Emerging Platforms, which reflects our larger offtake agreement with bp and stronger omega-3 results. On that note, Brendan and I, together with Rachel and Beth, are happy to take your questions.
Rico, I'd like to get you to expand on something you mentioned regarding the U.S. Crop Protection market, where you said there's a plan in place to boost returns and that it's being carried out right now. Could you give us some additional detail about the strategies you've put into practice in that North American market?
Yes, thank you for asking. It ties back to what we discussed in the presentation, which is essentially about concentrating on our portfolio. So we're altering the crop strategy as well as our portfolio strategy. In doing so, we're streamlining the portfolio we have in the U.S. market and shifting it toward products with higher margins; that will alter the margin profile of the U.S. Crop Protection business.
Could you give us a feel for a few of the products you're focusing on?
There may be a lengthy tail of items within our U.S. portfolio. And I think what we're really examining are the ones that have grown more commoditized — certain items that over the years became more commoditized and lost their relevance in the market. Those are the ones we're looking at; but I'll also maybe ask Beth to help explain a bit about what we're doing on our portfolio and crop strategy.
Thanks, Rico. Perhaps a bit more color on how we're approaching our crop strategy. We're centering that strategy on three core markets — cereals, soybeans, and tree nuts and vines — on a global basis, so that we can drive growth and margin improvement by putting resources behind those key groups. That mix accounts for the largest treated end-market value in Crop Protection. It also builds on what we do well in post-patent solutions and value-added mixtures across the regions, with a particular focus on cereals and soybeans in major markets such as Europe, North America, APAC and LATAM. The bulk of sales in our current pipeline ties back to these 3 crop groups, which shows how important they are, and by concentrating on them we get sharper portfolio prioritization, simpler registrations, better ROIs and more focused R&D. On top of that, our manufacturing footprint in phenoxies matters just as much in supporting these key crops. It's a key input for many cereal and soybean products on the market today, so even when prices move around, acreage stability in these key 2 crop segments gives us — supports base volumes, and that lifts asset utilization along with manufacturing and overhead.
That's great. I've got just one final question, and it concerns the cost-out programs. The '26 cost-out program, $50 million. '27, another $50 million. I'm just wondering whether this is, I suppose, a line in the sand that we should regard as a cost-out target we'll need going forward to keep offsetting inflationary pressures?
Yes. Thanks, Owen. This is Brendan. Regarding the 2026 cost-out program, as you can see from what we presented today, we've made really good progress on delivery so far, and that was mostly focused around the SG&A, and we're on plan to deliver the rest of that benefit in the second half. As for the extra $50 million that Rico mentioned as part of the strategy refresh, that is broader based in the sense of spanning the value chain. As Rico indicated, some of that benefit will come through in terms of cost of goods or manufacturing conversion costs as well as in our SG&A. There will be some reduction in our fixed cost base. We'll keep driving efficiency in the cost base that we have. Some of those benefits will be offset by inflationary pressures; that's an element that's hard to predict, but will be present, I suppose, going forward. So overall, from a cost perspective in terms of a theme in the strategy refresh is controlling the controllables when it comes to cost management, being disciplined about where we spend our money in terms of the benefit and the returns it provides, and we remain focused on our continuous efficiency right across the cost base as we go forward.
Could I ask about the trends you've observed in various geographies during the first 2 months of the second half so far, especially regarding the sorts of weather-related effects and, I suppose, the farm economics in those areas?
Thanks, Will. So, as we said, we're seeing solid momentum in April and May across every region and business in our company. On the weather front, we've observed — clearly, that elusive normal year we always discuss doesn't happen. There's always a mixed picture with things occurring in different places. But broadly speaking, weather conditions have been normal in that regard. So in Europe, we've had a somewhat late spring in certain parts of Europe, followed by flooding in a couple of southern markets; and in North America, we likewise experienced a late spring this year. So we're likely about 3 or four weeks behind a normal season in that region. And then in APAC, we've also seen dry weather have an impact at the start of the year. And now over the last couple of months, including in March, we got some good rainfall at the right point in the season from where we sit, and in the right geographies as well.
Can I follow up on strategy as well? What I'm getting at is, you've talked about how you're now going after — well, maybe not going after revenue, but putting greater weight on the quality of earnings. Looking at your global peers, they cite fairly muted revenue growth in Crop Protection, and it's volume-driven; and I'm not sure — I mean, this ties into what I asked earlier about farm economics. With cost inflation and diesel prices and all those things that are kind of outside their control, is there a danger that things shift toward cheaper, more commoditized products rather than some of the premium or higher-priced products you're talking about?
I don't think that's the case. My view of what's going on worldwide is that farmers definitely are worried about fuel costs climbing and, in particular, fertilizer prices going up. In my opinion, most farmers can choose to trim some of their fertilizer use if they've done the groundwork in earlier years. That means you're able to skip a year or cut back in a given year with no major effect on yield — and that's exactly what they're doing. They've got further ways as well to lower the cash they spend on the farm. They're tackling each of those challenges much like we do in running a business — they're keeping an eye on cash flow too. The one area where they appear unwilling to cut corners is the quality of the yields they rely on to deliver results on the farm. Farmers, then, stay committed to achieving high yields, and that drives them to put money into seeds. They also put money into crop protection so their crops are safeguarded, since after the investment has been made and the crop is in the ground, you have to make sure you can bring in the harvest and achieve the yields you're after. So I don't believe we're seeing — what we're seeing is no dramatic shift in the way farmers spend on crop protection and seeds.
Then, regarding how you're approaching, I suppose, your COGS within Crop Protection, when I consider some of the latest shifts in ag chem pricing coming from China, there's been a fairly significant improvement there. So how are you thinking about the benefits of prices rising and how they flow through to the business?
Yes, so much of that change we're seeing from China is clearly driven by the Middle East conflict, which affects their energy costs. What we haven't really seen is any short-term effect on our business. And historically, we've been quite effective at passing those cost increases through as higher prices for our products, and we'll keep managing that development coming from China, not only this year but next year as well.
And finally, I have one more question. How ought we to think about — I mean, I've seen that licensing revenue jumped in the half. How should we think about the licensing revenue profile going forward, roughly?
Licensing revenue is up year-on-year, though some movement has occurred. It mainly ties to the Emerging Platforms part of our business. Going forward, that will follow the pattern typical of what you see in the first half. That's <<inaudible>>.
Morning, everyone, and thanks for having me on for questions. Perhaps I'd like to begin with the growth platforms. Can you give us a sense of what initiatives are in place to bring down those breakeven costs for omega-3? And where do you expect those new costs to land compared with a breakeven price? If you could speak to that a bit.
Yeah, appreciate the question; we've discussed this in earlier settings as well, and really there are two things we're doing. First, perhaps I should note it isn't solely about lowering cost of goods — it's also about bringing down the CapEx spend. So what we did last year was take a hard look at the CapEx spend as well as the OpEx spend around the Emerging Platforms, and we acted on that, and we saw some of that happen last year too. Beyond that, we also made the decision to move production to South America. By doing so, we anticipate a lower cost to produce as a result of that decision. And finally, we're also waiting on deregulation in China, which will deliver additional cost savings for the omega-3 products.
All right. Could you give us some sense of that breakeven price compared with where it stood before, in light of those initiatives?
As a rule, we don't reveal the breakeven price. Clearly, competitors in this market are listening to these calls as well, so that's not something we typically discuss.
All right. For the second question, it's about the leverage guidance for the full year, near that 2x net debt to EBITDA; it does suggest a meaningful net working capital unwind in the second half. Perhaps you could help us bridge that unwind in the second half, the main drivers, and how we should think about leverage going into the new year too.
Yes. Thanks. This is Brendan. So we've confirmed regarding leverage at the end of financial year '26, that we will be at 2x EBITDA. What drives the ability to reach that leverage comes from net working capital; and as you said, on the capital — the net working capital unwind during the second half. That's typical of what we've seen in prior years, which is mostly driven by cash collections, effectively the reduction in receivables from sales made in the first half. There will be some inventory improvements as well. And as you can see from the first half, we've driven some working capital efficiency by reducing the cash conversion cycle. It will also be supported by a lower level of CapEx year-on-year. The weighting of that falls in the second half. That's largely because of project delivery, and it will also be supported by stronger earnings relative to last year too; in terms of looking beyond this current financial year, look, our message is about the focus on the continued commercial levers around driving better cash conversion in the business, sustaining the lower level of capital expenditure, continuing the improvement pathway that we have now sustained over approximately 2 years in driving lower working capital for the business and better cost control and a lower cost profile; so that's important, I guess, overall, in terms of the strategy refresh; we're building a better quality business with a stronger balance sheet, which will lead to continued deleveraging over time.
All right. One more item, and it concerns CapEx. At roughly $200 million, it now sits closer to D&A. Do you regard that as a level that can be sustained — for the foreseeable future, for the business — particularly in light of some of the initiatives you've mentioned regarding rationalizing product SKUs and putting capital to work more efficiently in the seeds businesses?
Yes, that's our view. For the business, we foresee holding spend at a lower, sustainable level below $200 million. Compared with earlier periods, which came after a stretch of sustained investment — especially in the manufacturing asset base — the requirements there are now behind us. We've also examined the Emerging Platforms, and we've communicated that investment will be lower, particularly in omega-3, since we've repositioned that business.
I was just wondering whether you could say something about channel inventory balances throughout the supply chain. We're hearing that these have been drawn down given the input cost inflation. I was wondering whether you'd also just touch on how you guys are managing inventory with the risk that the tariff floor was opened and this could see AI prices fall sharply.
Yes. So we are also seeing that inventories are being drawn down across the world. Obviously, people are hesitant to replenish their inventories with the cost we see out of China. So that's — we're also doing the same; we're seeing the same in the channel partners that they are looking also at inventory management.
Alright. And might that have helped your margins during the first half?
Pardon me. Would you mind saying that again? I couldn't quite catch it.
So as you work through that cheaper inventory, might that have been a factor behind the margins in the first half, or does the timing not really line up?
No. What moved the margin during the first half has more to do with the choices we made on rationalizing the portfolio; on top of that, portfolio mix shifted somewhat because of certain delays we encountered in North America during the season.
Great. Just one last thing: so with U.S. Crop Protection, you're working through the portfolio rationalization there. Australia is also a fairly large market, and it's also pretty competitive here. Are you doing further rationalization in other geographies?
So over the last few years we've been quite disciplined when it comes to rationalizing the portfolio in Australia. So globally, in any given year, we typically rationalize about 10% of our SKUs. So that's the normal rate. This year that number is going to be higher, probably even closer to 20%, mostly driven by what we are seeing in North America.
Can you hear me okay?
Yes.
Okay, so for my first question, may I just touch on omega-3? Clearly, you raised the guidance today on that equation; from what I recall of the sensitivities, that works out to roughly a couple hundred bucks per tonne on pricing, correct? And looking at the market — I mean, back in November last year when we were here, pricing in Peru and Chile sat at about $2,500 to $2,700 a tonne. As I see it now, it's roughly $4,600 to $5,000 a tonne, and it simply holds its fishing off the coast of Chile, and they've stopped it for 30 days off the coast of Peru.
Brendan speaking, Jonathan. The environment appears to be improving compared with where it stood half a year back, especially when you set it against the pricing you seem to be putting through. My first question, then: have I got the sensitivities on price right — is that what's been built into guidance? Second, you had a USD 90 million facility that was fully drawn at balance date last year; how are the markets treating you as you actually sell this material through at present? And are you seeing more interest from parties wanting longer-term offtake agreements? Regarding fish oil pricing, as we mentioned, prices have risen compared with six months ago and have generally firmed up; that improvement has carried through to the pricing of our Aquaterra product. We sold some volume during the first half and intend to sell additional volume in the second half. There is a trade-off involved in balancing short-term and longer-term opportunities. On the quota prices, those are spot prices in dollar terms and they also depend somewhat on volume, but there's no arguing with the fact that fish oil pricing has been strengthening and has risen over the last six months. On the guidance side, we're lifting the Emerging Platforms figure from $30 million up to $40 million, and that change is mostly driven by the same dynamic. On the $90 million facility, sales are already underway, and we plan to make more of them in the second half; those will support paying down the loan — $45 million of it matures in September of this year, and the rest comes fully due in September '27.
All right. Look, may I pick up on a few of the questions that have come up regarding actives right now? If I consider — when I think about your business, you max out that loan every March. Since March, prices in active markets have likely climbed close to 20% in Australian dollar terms. So I suppose somewhat more in U.S. dollar terms. I guess what folks are attempting to work out is whether there's almost a sort of free carry into the second half, given that obviously people would have been landing, or would be landing now, higher priced stock that competes against lower priced stock. Obviously, you wouldn't have seen any of that in the first half. Are you seeing any advantage from that at all in the second half, in that you're effectively carrying lower cost inventory compared with where spot pricing sits right now?
So as we discussed, there is a bit of what we mentioned earlier, which is that a bit of an inventory unwind is taking place, in the sense that people are hesitant about replenishing cost. But I don't see — certainly not in our case, we're not going out and engaging in what you could call predatory pricing, nothing of that sort, taking advantage of the oil market situation by adding pricing. That's not what we're doing. What we actually are doing is what we discussed earlier: we're seeing the effects of portfolio rationalization coming through in our margins by eliminating some of those low-margin products from our portfolio; that's really what's driving most of the margin increase. And then combined, as I said, we have a little bit of phasing going on from the delay in the spring in North America. That's also reflected in that change in margin. But it's — that's really the situation we have.
All right. Look, perhaps just one final question, since I believe I spotted something in the accounts — this time I wasn't able to locate the off-balance sheet facility utilization. Could you tell us what that figure came to in the first half? Does it contribute materially to cash flow, or does it not?
Jonathan, at the half that figure stood at $62 million. It's a financing facility that's available to our suppliers. And effectively, I'd characterize it as neutral when it comes to cash flow impacts.
It's good to see such a solid improvement in the first half result. Now, on the omega-3 price, could you tell us what your new assumption is within guidance compared with the previous $2,600? Then, moving to Crop Protection, could you talk about where you see the most upside, and which regions in the second half? And how should we think about corporate costs? Finally, what do you expect to realize from asset sales, please?
Belinda, it's Brendan here. I'll take your omega-3 question and corporate costs. So on omega-3, the position we had at the end of this time last year, in September, was to reflect effectively the prices current at that time. As for how — where we position Emerging Platforms and the omega-3 component of that within the platform, it reflects the prices current at this moment in time. On corporate costs, they're broadly flat at the half, and we expect the same result at the end of the year. I'll pass to Rico around trends.
Yes. So, as we discussed in the script, April and May showed really strong momentum for us, and those are significant months. That's part of what gives us confidence to reaffirm the outlook, but another part is that we're actually seeing gross margin improve along with better earnings, I should say, in crop protection during the second half. And then there's the fact that the dry weather conditions in Australia hurt us in the first half, and we don't expect that to recur in the second half. So those are the things that shift the result in the second half.
And as far as asset sales go, how should we think about possible proceeds?
Possible what, sorry?
As far as potential proceeds go, I suppose if we turn to asset sales and the proceeds from them, it's too early to put a value on that. You've got the recent announcement about the closure and sale of Kwinana, and that closure is expected in May of next year. As for any other asset rationalization or proposed rationalizations, those are pending decisions that will take their due course.
Mine should be a fairly brief question, hopefully. Rico, you discussed the effect on certain customers and a few of the cost increases they're facing. You mentioned your capacity to pass along the higher price of inputs. I'm curious whether you're seeing any possible shortages ahead for critical inputs into your products, please, and whether you could discuss what you're doing to handle a few of those risks, if you'd rather not name which specific chemicals they are, but simply speak more broadly about what you're doing to make sure you have product. You're plainly doing a solid job of passing through the cost increases, but just regarding ensuring that you're producing at all times, please.
Yes. Thank you. I think that's an interesting question. And if we look back at what took place when the conflict first erupted in the Middle East and the shift they brought about on supply chains, we observed very, very little impact; we had a small amount of some difficulties in sourcing packaging materials in a couple of markets; but all those short-term impacts we saw at that time, we've worked through that; and whatever impact there is on some of the raw materials that are based on petroleum and so on, that has already been mitigated, and it's also reflected in the fact that we are reaffirming our outlook for the full year.
Hopefully you can hear us this time.
Yes.
I've just got a couple of questions. Thanks. First off, on the ag chem industry more broadly, it's clearly been a highly competitive space these past few years. So what are you seeing now — is the environment becoming more rational, or not?
That's a genuinely interesting question, John. As I mentioned in the script earlier, it feels to us like the industry has moved toward an everything for everybody type of model — and that may well be part of why there have been these problems producing results over the last few years. We are seeing that certain companies are starting to act with more focus. And I think that will be a positive trend for the industry as a whole. That said, there is, of course, still the matter of the cost to serve, and I think some companies are finding it hard to improve their cost to serve. I think we have stayed really focused on controlling what we can control within our business, both in terms of delivering the balance sheet and in bringing our cost down to a more sustainable level, which is exactly what we're concentrating on right now; so I can't say precisely what decisions other companies ought to be making, but as I said, we're focused on what we can control and on making sure we're lowering our cost to serve and taking the right steps around our portfolio and becoming more focused on those parts of our portfolio and those markets where we know we have a right to win.
Then a quick follow-up for Brendan about FX. What FX assumptions sit behind your second-half earnings guidance? And clearly there was that $10 million FX hedging loss in interest. Could you give a little color on what that's tied to?
Yes. On the makeup of net financing expense in the P&L, when we break it down, our external interest on borrowings is down by a couple of million. And as you say, from an FX standpoint, that rose half-on-half. It's really that we saw more variable volatility around when the Middle East conflict began, and that has shaped the impact of it. So our hedging policy remains consistent when it comes to managing exposures. For the second half, we do see some stabilization, so we've tempered our view of what the impact will be in the second half. Sorry, was there a second part to your question, John? No. That was the first point, FX.
Yeah, that's roughly in line with what you're figuring for the second half of the year on FX in your guidance. So mainly from the standpoint of translating earnings.
Right. So we expect it to be smaller than what we — the effect lands in the first half, so you can figure it's about half the impact we saw in the first half.
And that relates to the interest side, Brendan?
Sorry — that's on the FX expense. And on the whole, as far as net interest expense goes, we've changed the financial year '26 figure to roughly $100 million.
Thanks, Ashley. So, to go over the results once more: we're really pleased with what we achieved in this first half, and we're reaffirming the outlook for the full year. As we mentioned earlier, we laid out those priorities for FY '26 back in November, and we're delivering on them — improving free cash flow, reducing leverage, and growing profitable products. So again, thank you for listening in. And thanks to our teams around the world who helped us deliver this result — thank you so much.
That brings today’s conference to a close. We appreciate your participation. You can disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nufarm Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Nufarm Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.